ClinicalTrials.gg
Enrolling by invitationNCT07673822Updated Jun 29, 2026

Prevalence and Overlap of Cardiovascular, Kidney, and Metabolic Diseases in Korea: A Population-based Study

An observational study in Diabetes Mellitus, Type 2, Obesity and Chronic Kidney Disease, sponsored by Novo Nordisk A/S. Enrolling by invitation at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Novo Nordisk A/S · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
800,000
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S — 27 open to participants now, 31 under way, 11 of them phase 3. Diabetes Mellitus, Type 2 · Novo Nordisk A/S.

Planned enrollment
Largest of 215
800,000 · median 938
Started
2026
with 24 others
Observational
215 of 645
9 open now
Primary completion
2026-08
later than 0 of 30 live
Registered
631st of 645
by date

Among the 645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one has the largest planned enrollment of the 215 observational ones that give a count, is one of 25 that started in 2026, is one of 215 observational ones, reaches primary completion later than 0 of the 30 other live ones, and was the 631st registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

27 of the 645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 27 open studies →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 19 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study tests the prevalence and characteristics of overlapping obesity, type 2 diabetes (T2D), cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic dysfunction-associated steatotic liver disease [MASLD/Metabolic Dysfunction-Associated Steatohepatitis (MASH)], osteoarthritis, hypertension, and dyslipidemia. The purpose of the study is to measure how common cardiovascular, kidney, and metabolic diseases are in the Korean adult population and how often they occur together (overlap) over time (2013-2023). Participants will not receive any study medicine as this is an observational analysis of existing survey data. The study does not involve a new investigational drug; it analyses health and outcome data collected in routine practice and national surveys.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Obesity
  • Chronic Kidney Disease
  • Cardiovascular Risk
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The participants in this study are drawn from Korean National Health Insurance Service (NHIS) - National Sample Cohort (NSC) aged 19 years and older. The eligible participants were selected by stratified random sampling in 2006 with follow-up through December 2023.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For an eligible participant, all inclusion criteria must be answered "yes".

Primary Analysis:

  1. Enrolled in the Korean National Health Insurance Service (NHIS) with valid insurance eligibility during the assessment year.
  2. Adults aged 19 years or older at the index date (January 1 of each assessment year, annually from 2013 to 2023).

Secondary Analysis (Subgroup Cohorts):

  1. Enrolled in the Korean National Health Insurance Service (NHIS) with valid insurance eligibility during the cohort entry year.
  2. Adults aged 19 years or older at the cohort entry date (i.e., the index date defined per the relevant subgroup cohort in) (per the SAP).
  3. Meets the operational definition of the index disease or state for one of the four pre-specified subgroup cohorts (MASLD, HF, CKM stage, or High obesity) (per the SAP).

Exclusion criteria

Exclusion Criteria:

  • For an eligible participant, all exclusion criteria must be answered "no".

Primary Analysis:

  1. Individuals with missing age or sex information in the NHIS database.
  2. Individuals with less than 1 year of continuous enrollment prior to the index date (to ensure adequate lookback period for disease identification).

Secondary Analysis (Subgroup Cohorts)

  1. Individuals with missing age or sex information in the NHIS database.
  2. Individuals with less than 1 year of continuous NHIS enrollment prior to the cohort entry date (to ensure adequate for incident-case ascertainment).
  3. Individuals with prior record of respective disease within the 1-year lookback window
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
800,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • MASLD

    Participants with MASLD where the date of first MASLD identification at biennial screening (2013-2018), after the greater than or equal to (≥) 1-year washout window; follow-up continues until death, loss of NHIS eligibility, or end of available data.

    Other: No treatment given

  • Heart Failure (HF)

    Participants for whom the date of first HF diagnosis is at biennial screening (2013-2028), after the ≥1-year washout window; follow-up continues for a minimum of 5 years from the index date.

    Other: No treatment given

  • CKM Stage

    Participants were categorized according to CKM staging (Stages 0-4), based on their CKM stage assessed at the initial national health screening, after the ≥1-year washout window; follow-up continues until death, loss of National Health Insurance Service (NHIS) eligibility, or end of available data.

    Other: No treatment given

  • High Obesity

    Participants with pre-specified obesity participants of interest tier that indicating significant overweight and were classified into three categories: 1) Body Mass Index (BMI) greater than or equal to (≥) 27 kg/m\^2 with established CVD. 2) BMI ≥27 kg/m\^2 with one or more obesity-related comorbidities. 3) BMI ≥25 kg/m\^2 and less than (\<) 30 kg/m\^2 with 1 or more obesity-related comorbidities.

    Other: No treatment given

  • Atherosclerotic Cardiovascular Disease (ASCVD) with or without CKD

    Participants with ASCVD where the first ASCVD identification occurred during biennial screening (2013-2018), after the ≥1-year washout window.

    Other: No treatment given

Interventions

  • OtherNo treatment given

    No treatment given

06

What researchers measure

Primary outcomes

  1. Proportion of participants with obesity (BMI ≥25 kilograms per square meter (kg/m^2))

    Measured in proportion (%).

    Time frame: 2013-2018 (Annually)

  2. Proportion of participants with T2D

    Measured in proportion (%).

    Time frame: 2013-2018 (Annually)

  3. Proportion of participants with hypertension

    Measured in proportion (%).

    Time frame: 2013-2018 (Annually)

  4. Proportion of participants with dyslipidemia

    Measured in proportion (%).

    Time frame: 2013-2018 (Annually)

  5. Proportion of participants with CVD (ASCVD, HF with atrial fibrillation, HF without atrial fibrillation)

    Measured in proportion (%).

    Time frame: 2013-2018 (Annually)

  6. Proportion of participants with CKD

    Measured in proportion (%).

    Time frame: 2013-2018 (Annually)

  7. Proportion of participants with MASLD; at-risk Metabolic Dysfunction-Associated Steatohepatitis (MASH)(within MASLD)

    Measured in proportion (%).

    Time frame: 2013-2018 (Annually)

  8. Proportion of participants with Osteoarthritis (OA)

    Measured in proportion (%).

    Time frame: 2013-2018 (Annually)

  9. Multi-disease overlap (≥2, ≥3 conditions)

    Measured in proportion (%).

    Time frame: 2013-2018 (Annually)

  10. Patient characteristics in obesity/diabetes-anchored strata

    Measured as descriptive statistics.

    Time frame: 2013-2018 (Annually)

Secondary outcomes

  1. Baseline characteristics by subgroup cohort

    Measured as descriptive statistics.

    Time frame: Cohort index date (2013-2018)

  2. All-cause mortality over cohort follow-up

    Measured in Hazard Ratio (HR).

    Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 yr potential follow up (FU))

  3. Healthcare resource utilization (HCRU) over cohort follow-up (Number of participants)

    Measured as outpatient visits, hospitalizations, and emergency room visits in terms of number of participants.

    Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 yr potential FU)

  4. Healthcare resource utilization (HCRU) over cohort follow-up (rates per person-year)

    Measured as outpatient visits, hospitalizations, and emergency room visits in terms of rates per person-year.

    Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 yr potential FU)

  5. Total medical costs over cohort follow-up (Mean)

    Measured as Cumulative total costs and annualized costs per person-year in terms of means with standard deviations.

    Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 yr potential FU)

  6. Total medical costs over cohort follow-up (Median)

    Measured as Cumulative total costs and annualized costs per person-year in terms of medians with Interquartile Range (IQR)

    Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 yr potential FU)

  7. Three-point major adverse cardiovascular events (3P-MACE) composite assessment for CV-death proxy, non-fatal myocardial infarction, and non-fatal stroke

    Measured in Hazard Ratio (HR).

    Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 yr potential (FU)

  8. Proportion of participants with baseline organ-axis phenotype distribution (HF cohort): ASCVD, renal, metabolic, hepatic axes

    Measured in proportion (%) by phenotype.

    Time frame: Cohort index date (2013-2018)

  9. Proportion of participants with GDMT prescription patterns, calendar-year trends, and prescription disparities (HF cohort)

    Measured in proportion (%).

    Time frame: Over cohort follow-up (2013-2023)

  10. Time to CKM stage progression (CKM stage cohort)

    Measured as median time to progression, if estimable; number and proportion with progression

    Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 years potential FU) to date of Progression

  11. Time to tier change (High obesity cohort)

    Measured as median time to tier change, if estimable; number and proportion with tier change.

    Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 years potential FU) to tier change

07

Study locations

1 site
  • Novo Nordisk Pharma Korea, Ltd.
    Seoul, 01000, South Korea
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Aug 2026, 1 month after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2026
First posted
Jun 29, 2026
StartActual
Jun 8, 2026
Primary completionEst.
Aug 3, 2026
CompletionEst.
Aug 3, 2026
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07673822
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jun 29, 2026
Start date
Jun 8, 2026
Primary completion
Aug 3, 2026 (estimated)
Completion
Aug 3, 2026 (estimated)
Last update
Jun 29, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion